26.02.2014 • News

BASF Has No Plans to Revive Share Buyback Scheme

Unlike U.S. rivals such as Dow Chemical and DuPont, BASF has no plans to revive its share buyback program, the German group's CEO Kurt Bock told Reuters Inside TV.

Interviewed in conjunction with the annual results press conference in Ludwigshafen on Feb. 25, Bock said BASF would prefer to spend the money on new plant and equipment.

"We pay a handsome dividend and then the money is being spent, frankly," the news agency quotes Bock as saying. "We are rightly leveraged, there is little money left for buybacks." From 1999-2008, BASF purchased around €10 billion worth of its own stock.

Bock said also that the group would continue to focus on technology-driven, smaller acquisitions.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

From Catalogue to Collaboration

Enamine's Expert Insights Collection Is Free to Download
Enamine’s 35 Years of Advancing Drug Discovery

Enamine's Expert Insights Collection Is Free to Download

From catalogue to collaboration — explore 35 years of drug discovery breakthroughs, novel building blocks, and the science shaping tomorrow's medicines. Download your complimentary copy now.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.